Data from one of the quality of life measurements collected from
colorectal cancer patients enrolled in the North Central Cancer Treatment Group
phase III trials N9741. The patient received three treatment regimens:
IFL (irinotecan, bolus fluorouracil, and leucovorin), FOLFOX (infused
fluorouracil, leucovorin, and ocaliplatin), and IROX (irinotecan and oxaliplatin).